Is it possible to avoid AMD?

Written by: Mr Praveen Patel
Published:
Edited by: Nicholas Howley

Age-related macular degeneration (AMD) affects over half a million people in the UK and is on the rise. We asked internationally recognised ophthalmologist Mr Praveen Patel what is behind this increase and if there is anything that patients can do to reduce their risk.

How common is age-related macular degeneration?

Age-related macular degeneration (AMD) is the most common cause of sight impairment and blind registration in the UK.

The prevalence of AMD increases with age and estimates suggest that there are over 600,000 people living with AMD in the UK. With the number of people living into their 80s and beyond set to rise, AMD is becoming increasingly common.

What risk factors are associated with AMD?

There are several known risk factors associated with AMD.

We know that age is the biggest risk factor for AMD. However, there are many fortunate people in their 90s who don’t have AMD while there are also unfortunate people who have lost vision due to AMD in their late 50s or early 60s. This tells us that age is not the only risk factor when it comes to developing AMD.

Genetics also plays a huge role. Doctors and scientists have discovered over 15 different genes which may play a role in increasing or decreasing the development of AMD. Furthermore, for each gene there may be several different forms of changes which may increase or decrease the risk of AMD.

The involvement of many different genes, each with forms which increase or decrease the risk of AMD, also means that sometimes AMD does not simply pass from parent to their children as can be the case for diseases in which 1 gene causes the disease.

The “polygenetic” nature of AMD genetic risk means that it is very difficult to calculate the risk of AMD passing from one generation to the next in a family.

Can you avoid AMD?

We can’t do much about getting older or the genes we inherit from our parents, but there are things we can do to reduce the risk of AMD.

We know that smoking is the biggest modifiable risk factor for AMD so this provides another good reason to reduce or give up smoking. We also know that a diet in green leafy vegetables such as kale and broccoli can help reduce the risk of AMD developing. The role of vitamin supplements remains controversial and it is not currently possible to recommend a particular supplement.

How important is it to look after our eyes?

It’s extremely important to look after our eyes and our vision and a lot of people take their sight for granted. It’s important to have regular eye tests, and if there are risk factors or concerns about AMD then a retinal optical coherence tomography (OCT) scan can help detect the earliest stages of AMD.

To book an assessment with Mr Patel, click here .

By Mr Praveen Patel
Ophthalmology

Mr Praveen Patel is an internationally-revered and award-winning consultant ophthalmologist based in central LondonSawbridgeworth, Hertfordshire and St Albans. He specialises in macular degeneration (AMD), retinas and retinal vein occlusion alongside diabetic retinopathy, macular oedema and intravitreal injection. He privately practices for Moorfields Private Outpatients Centre, The Rivers Hospital, London Medical and the Eyesight Clinic at the Redbourn Health Centre. He also works for the NHS at the world-renowned Moorfields Eye Hospital in London.

Mr Patel is passionate about providing cutting-edge treatments for patients on the NHS and privately. He is the lead consultant for medical retina clinical trials and retinal imaging at Moorfields Eye Hospital and the age-related macular degeneration treatment service at the Princess Alexandra Hospital Trust, in partnership with Moorfields Eye Hospital. 

Mr Patel, who has a special interest in cataracts and retinal and macular disease, qualified from Cambridge University in 1997 with a first class degree. This was followed by postgraduate training in Ophthalmology at Moorfields Eye Hospital, London.   
 
Mr Patel has an esteemed reputation for excellence in patient care for macular disease, including the use of the injectable medications Lucentis, Eylea and Ozurdex as well as Avastin. Verteporfin photodynamic therapy and advanced macular laser treatments are also incorporated into his skilful practice. His clinical research reflects his expertise to the highest standard; Mr Patel won the Moorfields Research Medal for his work, as one of the lead investigators for the world's first randomised trial of Avastin for age-related macular degeneration, which was published in the British Medical Journal (BMJ).

His research work has also extended to validating new imaging modalities for the assessment of macular disease and he is a clinical research fellow at Moorfields and at the UCL Institute of Ophthalmology.

Mr Patel's work has been published in various peer-reviewed journals and he is an international member of the Association for Research in Vision & Ophthalmology (ARVO) and member of the American Academy of Ophthalmology (AAO) and the Royal Society of Medicine (RSM). He is also a fellow of the Royal College of Ophthalmologists.

View Profile

Overall assessment of their patients


  • Related procedures
  • Microdermoabrasion
    Microneedling
    Dark circles
    Mesotherapy
    Facelift
    Neck lift
    Botulinum toxin (Botox™)
    Dermal fillers
    Peeling
    Facial paralysis
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.